Aspire Biopharma Holdings, Inc.
ASBP
$0.3366
-$0.0277-7.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -61.54% | 121.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -43.87% | 122.51% | |||
| Operating Income | 43.87% | -122.51% | |||
| Income Before Tax | 87.57% | -2,058.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 87.57% | -2,058.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 87.57% | -2,058.61% | |||
| EBIT | 43.87% | -122.51% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 90.44% | -24,647.06% | |||
| Normalized Basic EPS | 31.44% | -2,890.00% | |||
| EPS Diluted | 90.44% | -24,647.06% | |||
| Normalized Diluted EPS | 31.44% | -2,890.00% | |||
| Average Basic Shares Outstanding | 30.20% | -91.39% | |||
| Average Diluted Shares Outstanding | 30.20% | -91.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||